HK1174629A1 - Benzoxazepin pi3k inhibitor compounds and methods of use pi3k - Google Patents

Benzoxazepin pi3k inhibitor compounds and methods of use pi3k

Info

Publication number
HK1174629A1
HK1174629A1 HK13101739.9A HK13101739A HK1174629A1 HK 1174629 A1 HK1174629 A1 HK 1174629A1 HK 13101739 A HK13101739 A HK 13101739A HK 1174629 A1 HK1174629 A1 HK 1174629A1
Authority
HK
Hong Kong
Prior art keywords
pi3k
methods
benzoxazepin
inhibitor compounds
pi3k inhibitor
Prior art date
Application number
HK13101739.9A
Other languages
English (en)
Chinese (zh)
Inventor
Nicole Blaquiere
Steven Do
Danette Dudley
Adrian J Folkes
Robert Heald
Timothy Heffron
Mark Jones
Aleksandr Kolesnikov
Chudi Ndubaku
Alan G Olivero
Stephen Price
Steven Staben
Lan Wang
Original Assignee
霍夫曼-拉羅奇有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43037239&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1174629(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 霍夫曼-拉羅奇有限公司 filed Critical 霍夫曼-拉羅奇有限公司
Publication of HK1174629A1 publication Critical patent/HK1174629A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK13101739.9A 2009-09-28 2013-02-07 Benzoxazepin pi3k inhibitor compounds and methods of use pi3k HK1174629A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24638109P 2009-09-28 2009-09-28
US33068510P 2010-05-03 2010-05-03
PCT/EP2010/064208 WO2011036280A1 (en) 2009-09-28 2010-09-27 Benzoxazepin pi3k inhibitor compounds and methods of use

Publications (1)

Publication Number Publication Date
HK1174629A1 true HK1174629A1 (en) 2013-06-14

Family

ID=43037239

Family Applications (2)

Application Number Title Priority Date Filing Date
HK15112815.1A HK1211929A1 (en) 2009-09-28 2013-02-07 Benzoxazepin pi3k inhibitor compounds and methods of use pi3k
HK13101739.9A HK1174629A1 (en) 2009-09-28 2013-02-07 Benzoxazepin pi3k inhibitor compounds and methods of use pi3k

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK15112815.1A HK1211929A1 (en) 2009-09-28 2013-02-07 Benzoxazepin pi3k inhibitor compounds and methods of use pi3k

Country Status (32)

Country Link
US (7) US8242104B2 (ja)
EP (3) EP2711368B1 (ja)
JP (2) JP5540101B2 (ja)
KR (1) KR101428346B1 (ja)
CN (2) CN104744491B (ja)
AR (1) AR078187A1 (ja)
AU (1) AU2010299816C1 (ja)
BR (1) BR112012006807A2 (ja)
CA (1) CA2772691C (ja)
CL (1) CL2012000754A1 (ja)
CO (1) CO6491026A2 (ja)
CR (1) CR20120121A (ja)
DK (1) DK2483278T3 (ja)
EC (1) ECSP12011755A (ja)
ES (2) ES2444779T3 (ja)
HK (2) HK1211929A1 (ja)
HR (1) HRP20140229T1 (ja)
IL (2) IL217558A (ja)
MA (1) MA33531B1 (ja)
MX (1) MX2012003591A (ja)
MY (2) MY160064A (ja)
NZ (1) NZ597833A (ja)
PE (1) PE20121025A1 (ja)
PL (1) PL2483278T3 (ja)
PT (1) PT2483278E (ja)
RS (1) RS53164B (ja)
RU (2) RU2654068C1 (ja)
SG (1) SG10201405049RA (ja)
SI (1) SI2483278T1 (ja)
TW (1) TWI423980B (ja)
WO (1) WO2011036280A1 (ja)
ZA (1) ZA201202199B (ja)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2774715C (en) 2009-07-27 2018-04-03 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
US8263633B2 (en) * 2009-09-28 2012-09-11 F. Hoffman-La Roche Ag Benzoxepin PI3K inhibitor compounds and methods of use
ES2444779T3 (es) * 2009-09-28 2014-02-26 F. Hoffmann-La Roche Ag Compuestos de benzoxazepina inhibidores de la PI3K y su utilización en el tratamiento de cáncer
CN103096977B (zh) 2010-07-02 2017-02-15 吉利德科学公司 作为离子通道调节剂的稠杂环化合物
EP2688891B1 (en) 2011-03-21 2017-11-15 F. Hoffmann-La Roche AG Benzoxazepin compounds selective for pi3k p110 delta and methods of use
CA2834164A1 (en) 2011-05-10 2012-11-15 Gilead Sciences, Inc. Fused benzoxazinones as ion channel modulators
WO2012156379A1 (en) 2011-05-13 2012-11-22 Universität Zürich PIK3/P110α INHIBITORS FOR PREVENTION OF RESTENOSIS BY APPLICATION AS AN IMPLANT COATING
TWI478908B (zh) 2011-07-01 2015-04-01 Gilead Sciences Inc 作為離子通道調節劑之稠合雜環化合物
NO3175985T3 (ja) * 2011-07-01 2018-04-28
EP2814830A1 (en) * 2012-02-17 2014-12-24 F.Hoffmann-La Roche Ag Tricyclic compounds and methods of use therefor
NZ702244A (en) * 2012-06-08 2017-06-30 Hoffmann La Roche Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer
WO2014004376A2 (en) 2012-06-26 2014-01-03 Del Mar Pharmaceuticals Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
CN102775395A (zh) * 2012-07-12 2012-11-14 江苏七洲绿色化工股份有限公司 一种丙环唑的制备方法及丙环唑中间体
IN2015DN00659A (ja) * 2012-08-07 2015-06-26 Janssen Pharmaceutica Nv
AU2014230812B2 (en) * 2013-03-13 2016-04-07 F. Hoffmann-La Roche Ag Process for making benzoxazepin compounds
KR20160061911A (ko) 2013-04-08 2016-06-01 데니스 엠. 브라운 최적하 투여된 화학 화합물의 치료 효과
WO2015091305A1 (en) * 2013-12-16 2015-06-25 F. Hoffmann-La Roche Ag Polymorphs of 2-(4-(2-(1-isopropyl-3-methyl-1h-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)-1h-pyrazol-1-yl)-2-methylpropanamide, methods of production, and pharmaceutical uses thereof
KR20160124909A (ko) 2014-03-13 2016-10-28 에프. 호프만-라 로슈 아게 에스트로겐 수용체 조절제를 함유하는 치료 조합물
SG10202100916PA (en) 2015-02-02 2021-02-25 Valo Early Discovery Inc 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as hdac inhibitors
US10183934B2 (en) 2015-02-02 2019-01-22 Forma Therapeutics, Inc. Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors
AR104068A1 (es) 2015-03-26 2017-06-21 Hoffmann La Roche Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer
JP6691552B2 (ja) * 2015-04-30 2020-04-28 ノバルティス アーゲー ファルネソイドｘ受容体をモジュレートするのに有用である縮合三環式ピラゾール誘導体
WO2017001362A1 (en) 2015-06-29 2017-01-05 F. Hoffmann-La Roche Ag Methods of treatment with taselisib
TW202108592A (zh) * 2015-07-02 2021-03-01 瑞士商赫孚孟拉羅股份公司 苯并氧氮呯噁唑啶酮化合物及其用途
CN107995911B (zh) * 2015-07-02 2020-08-04 豪夫迈·罗氏有限公司 苯并氧氮杂*噁唑烷酮化合物及其使用方法
WO2017042182A1 (en) * 2015-09-08 2017-03-16 F. Hoffmann-La Roche Ag Tricyclic pi3k inhibitor compounds and methods of use
US9721369B2 (en) * 2015-09-15 2017-08-01 Facebook, Inc. Systems and methods for utilizing multiple map portions from multiple map data sources
EP3472131B1 (en) 2016-06-17 2020-02-19 Forma Therapeutics, Inc. 2-spiro-5- and 6-hydroxamic acid indanes as hdac inhibitors
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
CN109982999A (zh) 2016-09-29 2019-07-05 拜耳作物科学股份公司 新的5-取代的咪唑基甲基衍生物
SI3555107T1 (sl) * 2016-12-15 2021-07-30 F. Hoffmann-La Roche Ag Postopek za pripravo (S)-2-((2-((S)-4(difluorometil)-2-oksooksazolidin-3-il)-5,6-dihidrobenzo (f)imidazo(1,2-d)(1,4)oksazepin-9-il)amino) propanamida
WO2018160654A2 (en) 2017-03-02 2018-09-07 Genentech, Inc. Adjuvant treatment of her2-positive breast cancer
JP6998969B2 (ja) 2017-04-28 2022-02-10 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト （ｓ）－２－（（２－（（ｓ）－４－（ジフルオロメチル）－２－オキソオキサゾリジン－３－イル）－５，６－ジヒドロベンゾ［ｆ］イミダゾ［１，２－ｄ］［１，４］オキサゼピン－９－イル）アミノ）プロパンアミドの多形体及び固体形態と、生産方法
IL274027B2 (en) * 2017-10-26 2023-12-01 Xynomic Pharmaceuticals Inc B–RAF kinase inhibitor salt crystals
EP3805231A4 (en) * 2018-05-30 2022-01-12 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. INHIBITOR CONTAINING A TRICYCLIC DERIVATIVE, METHOD FOR PREPARING IT AND ITS APPLICATION
CN111909157B (zh) * 2019-05-07 2023-02-03 南京药石科技股份有限公司 Ezh2抑制剂及其用途
WO2021088845A1 (zh) * 2019-11-04 2021-05-14 贝达药业股份有限公司 咪唑烷酮类化合物及其制备方法与应用
WO2021088839A1 (zh) * 2019-11-04 2021-05-14 贝达药业股份有限公司 咪唑烷酮类化合物及其制备方法与应用
EP4067363A4 (en) * 2019-11-25 2023-12-27 Shanghai Hansoh Biomedical Co., Ltd. SALT OR CRYSTAL FORM HAVING THREE CONDENSED RINGS AND PHARMACEUTICAL COMPOSITION THEREOF
IL308459A (en) 2021-05-13 2024-01-01 Betta Pharmaceuticals Co Ltd A polymorph of an imidazolidinone compound, its preparation method and use
AU2022282440A1 (en) 2021-05-28 2023-11-16 Genentech, Inc. Process for the preparation of benzoxazepin oxazolidinone compounds
WO2024104435A1 (zh) * 2022-11-17 2024-05-23 微境生物医药科技(上海)有限公司 三并环类PI3Kα抑制剂及其制备方法和医药用途

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
GB8504702D0 (en) 1985-02-23 1985-03-27 Zyma Sa Tricyclic compounds
US5583024A (en) 1985-12-02 1996-12-10 The Regents Of The University Of California Recombinant expression of Coleoptera luciferase
FR2677356B1 (fr) 1991-06-05 1995-03-17 Sanofi Sa Derives heterocycliques d'acylamino-2 thiazoles-5 substitues, leur preparation et compositions pharmaceutiques en contenant.
EP0638071B1 (en) 1992-12-28 1997-04-09 Eisai Co., Ltd. Heterocyclic carbonic acid derivatives which bind to retinoid receptors (rar)
AU678503B2 (en) * 1993-09-24 1997-05-29 Takeda Chemical Industries Ltd. Condensed heterocyclic compounds and their use as squalene synthetase inhibitors
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
JPH08336393A (ja) 1995-04-13 1996-12-24 Mitsubishi Chem Corp 光学活性なγ−置換−β−ヒドロキシ酪酸エステルの製造法
US5985799A (en) 1995-11-17 1999-11-16 E.I. Du Pont De Nemours And Company Tricyclic herbicidal heterocycles
US6602677B1 (en) 1997-09-19 2003-08-05 Promega Corporation Thermostable luciferases and methods of production
DE19908538A1 (de) 1999-02-26 2000-08-31 Aventis Pharma Gmbh Polycyclische 2-Amino-Thiazol Systeme, Verfahren zu ihrer Herstellung und Arzneimittel enthaltend diese Verbindungen
DE19908537A1 (de) 1999-02-26 2000-08-31 Aventis Pharma Gmbh Verwendung von polycyclischen 2-Amino-Thiazol Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
DE19908535A1 (de) 1999-02-26 2000-08-31 Aventis Pharma Gmbh Verwendung von polycyclischen Thiazol-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
DE19908533A1 (de) 1999-02-26 2000-08-31 Aventis Pharma Gmbh Polycyclische Thiazol-Systeme, Verfahren zu ihrer Herstellung und Arzneimittel enthaltend diese Verbindungen
US7273880B2 (en) 1999-06-30 2007-09-25 H. Lunbeck A/S Selective NPY (Y5) antagonists
AU2001246494A1 (en) 2000-03-03 2001-09-12 Novartis Ag Condensed thiazolamines and their use as neuropeptide y5 antagonists
EP1355875A1 (en) 2001-02-02 2003-10-29 Schering Corporation 3,4-di-substituted cyclobutene-1, 2-diones as cxc chemokine receptor antagonists
TWI232863B (en) * 2001-06-11 2005-05-21 Akzo Nobel Nv Benzoxazepine derivatives
US20040082602A1 (en) 2002-07-19 2004-04-29 Hagen Timothy J. Substituted thiophene carboxamide compounds for the treatment of inflammation
WO2004069245A1 (en) 2003-02-07 2004-08-19 Warner-Lambert Company Llc Oxazolidinone derivates n-substituted by a tricyclic ring, for use as antibacterial agents
TW200510356A (en) * 2003-08-01 2005-03-16 Takeda Chemical Industries Ltd Benzoxaepine compounds
US20050239767A1 (en) 2003-10-28 2005-10-27 Chan Michael K Intermolecular SNAr of the heterocycle-activated nitro and fluoro groups-application in the synthesis of polyazamacrocyclic ligands
MXPA06015275A (es) * 2004-07-01 2007-03-15 Merck & Co Inc Inhibidores de quinasa mitotica.
CA2579279C (en) 2004-10-07 2013-10-01 Boehringer Ingelheim International Gmbh Tricyclic thiazole derivatives as pi3 kinases
EA025871B9 (ru) 2005-10-07 2017-08-31 Экселиксис, Инк. Ингибиторы mek и способы их применения
US20070238746A1 (en) * 2006-04-06 2007-10-11 Trixi Brandl Thiazolyl-dihydro-chinazoline
US20070238718A1 (en) * 2006-04-06 2007-10-11 Matthias Grauert Thiazolyl-dihydro-indazole
GB0610866D0 (en) * 2006-06-02 2006-07-12 Hammersmith Imanet Ltd Novel in vivo imaging compounds
WO2008014483A1 (en) * 2006-07-28 2008-01-31 Alcan Packaging Flexible France Coextruded film with polylactic acid (pla) and ethylene vinyl acetate (eva)
EP2054058B1 (en) 2006-08-04 2016-11-09 Beth Israel Deaconess Medical Center Inhibitors of pyruvate kinase and methods of treating disease
US8779154B2 (en) 2006-09-26 2014-07-15 Qinglin Che Fused ring compounds for inflammation and immune-related uses
JP5295976B2 (ja) * 2006-12-29 2013-09-18 アボット ゲーエムベーハー ウント カンパニー カーゲー カルボキサミド化合物およびカルパイン阻害剤としてのこれらの使用
US8101740B2 (en) 2007-09-19 2012-01-24 The Regents Of The University Of California Positron emission tomography probes for imaging immune activation and selected cancers
KR101626996B1 (ko) * 2008-03-31 2016-06-02 제넨테크, 인크. 벤조피란 및 벤족세핀 ｐｉ３ｋ 저해제 화합물 및 이의 사용 방법
US8653097B2 (en) * 2008-10-17 2014-02-18 Boehringer Ingelheim International Gmbh Tetra-aza-heterocycles as phosphatidylinositol-3-kinases (P13-kinases) inhibitor
ES2444779T3 (es) * 2009-09-28 2014-02-26 F. Hoffmann-La Roche Ag Compuestos de benzoxazepina inhibidores de la PI3K y su utilización en el tratamiento de cáncer
US8263633B2 (en) * 2009-09-28 2012-09-11 F. Hoffman-La Roche Ag Benzoxepin PI3K inhibitor compounds and methods of use

Also Published As

Publication number Publication date
HK1211929A1 (en) 2016-06-03
BR112012006807A2 (pt) 2020-11-03
ECSP12011755A (es) 2012-05-30
US20140058098A1 (en) 2014-02-27
US20160052933A1 (en) 2016-02-25
KR20120065431A (ko) 2012-06-20
RU2654068C1 (ru) 2018-05-16
RU2012117398A (ru) 2013-11-10
US20130079331A1 (en) 2013-03-28
US20140288047A1 (en) 2014-09-25
MA33531B1 (fr) 2012-08-01
EP2845592A1 (en) 2015-03-11
RU2600927C2 (ru) 2016-10-27
US8785626B2 (en) 2014-07-22
CA2772691C (en) 2017-10-03
JP2014070075A (ja) 2014-04-21
NZ597833A (en) 2014-01-31
CO6491026A2 (es) 2012-07-31
US9670228B2 (en) 2017-06-06
PT2483278E (pt) 2014-03-05
AU2010299816A1 (en) 2012-02-02
ZA201202199B (en) 2013-01-30
TWI423980B (zh) 2014-01-21
AU2010299816C1 (en) 2018-02-01
PE20121025A1 (es) 2012-08-06
CN104744491A (zh) 2015-07-01
US20120244149A1 (en) 2012-09-27
MX2012003591A (es) 2012-04-19
ES2570569T3 (es) 2016-05-19
EP2711368B1 (en) 2016-03-23
AR078187A1 (es) 2011-10-19
IL217558A (en) 2015-06-30
DK2483278T3 (da) 2014-01-13
US9546178B2 (en) 2017-01-17
IL239081B (en) 2018-05-31
EP2483278B1 (en) 2013-12-25
PL2483278T3 (pl) 2014-05-30
JP5540101B2 (ja) 2014-07-02
JP2013505917A (ja) 2013-02-21
WO2011036280A1 (en) 2011-03-31
JP5625101B2 (ja) 2014-11-12
US20170081341A1 (en) 2017-03-23
CL2012000754A1 (es) 2012-09-07
CN102762576B (zh) 2015-04-22
TW201127844A (en) 2011-08-16
MY184074A (en) 2021-03-17
KR101428346B1 (ko) 2014-08-07
HRP20140229T1 (hr) 2014-04-11
US20110076292A1 (en) 2011-03-31
US8242104B2 (en) 2012-08-14
US9198918B2 (en) 2015-12-01
AU2010299816B2 (en) 2015-11-12
CR20120121A (es) 2012-06-01
ES2444779T3 (es) 2014-02-26
CA2772691A1 (en) 2011-03-31
US8343955B2 (en) 2013-01-01
EP2711368A1 (en) 2014-03-26
RS53164B (en) 2014-06-30
US8586574B2 (en) 2013-11-19
CN104744491B (zh) 2017-07-11
CN102762576A (zh) 2012-10-31
IL217558A0 (en) 2012-02-29
MY160064A (en) 2017-02-15
SI2483278T1 (sl) 2014-03-31
SG10201405049RA (en) 2014-10-30
EP2483278A1 (en) 2012-08-08
IL239081A0 (en) 2015-07-30

Similar Documents

Publication Publication Date Title
IL239081A0 (en) Benzoxazepine pi3k inhibitor compounds and methods of use
HK1216529A1 (zh) 苯並氧雜䓬 抑制劑化合物和使用方法
HRP20150127T1 (en) Tricyclic pi3k inhibitor compounds and methods of use
HK1172896A1 (zh) 化合物和使用方法
ZA201007524B (en) Purine pi3k inhibitor compounds and methods of use
HK1161094A1 (en) Compounds and methods of use
HK1168349A1 (en) Benzoxazepines as inhibitors of pi3k/m tor and methods of their use and manufacture
IL220154A0 (en) Novel pyrimidine compounds as mtor and pi3k inhibitors
IL207843A0 (en) Raf inhibitor compounds and methods of use thereof
SG10201405568UA (en) 4-substituted pyridin-3-yl-carboxamide compounds and methods of use
IL222227A0 (en) Pyrazol - 4 - heterocyclyl-carboxamide compounds and methods of use
IL213596A0 (en) Heterocyclic compounds and methods of use
EP2464227A4 (en) COMPOUNDS AND METHODS OF USE
EP2385944A4 (en) FLUORINATED COMPOUNDS AND METHODS OF USE
EP2242854A4 (en) COMPOUNDS AND USES THEREOF
EP2385943A4 (en) FLUORINATED COMPOUNDS AND METHODS OF USE
IL217756A0 (en) Inhibitors of jnk
EP2406244A4 (en) ESTROGEN COMPOUNDS AND METHOD FOR THEIR USE
EP2291347A4 (en) MANUFACTURE AND USE OF ALKYL P-TOLUATES
EP2344454A4 (en) ANTIOXIDATION COMPOUNDS AND METHOD FOR THEIR USE
GB0908609D0 (en) New use of isoQC inhibitors
GB0803895D0 (en) Inhibitors of glyoxalase